Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looking for $AVCO updates in the near future...
“Given our rapid progress this past year, our goal for 2022 is to focus on our core programs to drive innovation and bring about advanced technologies and new medicines to patients."
$AVCO trading just over 30% of its 10-day average volume with less than 3 hours left in the day...2022 looks to be a good year.
As we head into 2022, we believe we have a number of important upcoming milestones that have the potential to continue to drive significant value for our shareholders
I especially love this part of the $AVCO PR...
As we head into 2022, we believe we have a number of important upcoming milestones that have the potential to continue to drive significant value for our shareholders
AVCO is set up deliver key milestones in 2022 that should optimize revenue growth as we saw detailed in the most recent company news. This is a very good time to be paying attention here.
From the January 4th AVCO update:
"Given our rapid progress this past year, our goal for 2022 is to focus on our core programs to drive innovation and bring about advanced technologies and new medicines to patients. Towards this end, we have decided not to move ahead with the SenlangBio acquisition. Instead, we plan to focus our resources on organic growth and strategic partnership opportunities that we believe will hold the potential to drive much greater value for our shareholders, while avoiding potentially significant dilution that would have occurred with the proposed acquisition. Through strategic investments, we intend to continue to bring high-quality, high-impact programs to enrich Avalon's assets in intellectual properties, R&D and commercialization. Overall, we believe we are extremely well positioned to execute on our growth strategy, and I am highly encouraged by the operational and financial outlook for our business. Last week, we announced that our Chairman converted his loan to common stock at a significant premium to market, showing his further support and confidence in the business. As we head into 2022, we believe we have a number of important upcoming milestones that have the potential to continue to drive significant value for our shareholders," concluded Dr. Jin.
$AVCO red to green to red...it's trading just under 30% of its 10-day average volume and providing an opportunity to load cheaper shares.
Loading zone here, thin on the ask!
AVCO
$AVCO trading just under its 10-day average volume with less than 3 hours left in the day, UP almost 2%. Very stable volume here...
$AVCO trading just under half of its average volume within the first hour, UP over 4%...nice start to the day.
$AVCO holding steady in this market downturn...very nice 2021 update, and 2022 guidance.
“Given our rapid progress this past year, our goal for 2022 is to focus on our core programs to drive innovation and bring about advanced technologies and new medicines to patients. Towards this end, we have decided not to move ahead with the SenlangBio acquisition. Instead, we plan to focus our resources on organic growth and strategic partnership opportunities that we believe will hold the potential to drive much greater value for our shareholders, while avoiding potentially significant dilution that would have occurred with the proposed acquisition.
Avalon’s Chairman converts $3.0 million of debt into common stock at $1.25 per share showing continued confidence and support of the business $AVCO
Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs
January 4, 2022 (Globe Newswire)
Company continues to expand and accelerate its R&D strategies for high-impact translational and clinical programs in the US and Europe
Intended SenlangBio acquisition terminated, eliminating potential 80 million share issuance
Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today provided a year-end business update.
"We believe we have made significant progress in 2021, advancing our scientific and clinical programs focusing on immuno-oncology and cellular medicines," said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. "Our goal is to address the unmet needs of patients utilizing innovative technologies that transform cellular therapy and regenerative medicine. We have partnered with world-renowned research centers and universities on cutting edge research, and are accelerating our own innovative research, bio-process development, clinical programs and product commercialization."
Avalon entered into a new collaboration with University of Pittsburgh Medical Center (UPMC) to develop new cancer immunotherapy approaches and streamline manufacturing processes to bring these powerful treatments to cancer patients with a rapid bio-manufacturing time (1-2 days instead of weeks). Avalon's lead candidate, AVA-011, combines Avalon's FLASH-CAR(TM) technology with an innovative messenger ribonucleic acid (mRNA)-based technology platform, and is currently at an IND-enabling stage. Avalon is on track to initiate AVA-011 first-in-human clinical trial by mid-2022. This non-viral, next-generation chimeric antigen receptor (CAR)-based cellular therapies approach is expected to streamline and enhance the quality of clinical-grade CAR T-cell manufacturing and the Company believes will result in efficacious, lower cost cellular therapy products, making them accessible to a wider range of cancer patients.
Avalon's research partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria, is rapidly progressing. The co-development of a novel, cell-free, in-silico system with BOKU expands Avalon's ability to design and produce novel cell membrane proteins--including receptors found on the surface of immune cells and cancer cells that function in cell signaling and are important drug targets. This system also provides Avalon with an efficient tool to screen and optimize potential therapeutic targets.
Avalon has co-developed and jointly filed a patent with BOKU on a novel platform of S-layer coated emulsome technology (SLET) for next-generation, targeted drug delivery and cellular immunotherapy applications. The Company believes this novel SLET platform will help accelerate the development of Avalon's mRNA-based Flash-CAR(TM) and other cellular therapy programs. Targeted delivery of mRNA into immune effector cells using SLET can potentially open the door to new generation of cancer immunotherapy and other applications including targeted drug delivery and therapeutics, vaccine development, in vitro diagnostics, and cellular medicines.
"Given our rapid progress this past year, our goal for 2022 is to focus on our core programs to drive innovation and bring about advanced technologies and new medicines to patients. Towards this end, we have decided not to move ahead with the SenlangBio acquisition. Instead, we plan to focus our resources on organic growth and strategic partnership opportunities that we believe will hold the potential to drive much greater value for our shareholders, while avoiding potentially significant dilution that would have occurred with the proposed acquisition. Through strategic investments, we intend to continue to bring high-quality, high-impact programs to enrich Avalon's assets in intellectual properties, R&D and commercialization. Overall, we believe we are extremely well positioned to execute on our growth strategy, and I am highly encouraged by the operational and financial outlook for our business. Last week, we announced that our Chairman converted his loan to common stock at a significant premium to market, showing his further support and confidence in the business. As we head into 2022, we believe we have a number of important upcoming milestones that have the potential to continue to drive significant value for our shareholders," concluded Dr. Jin.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX(TM)), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare's developments, please follow our twitter at @avalongc_avco
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
avco@crescendo-ir.com
Pretty good choice , hes doubled the investment so far. $avco break above 3 coming soon
News Out! Avalon’s Chairman converts $3.0 million of debt into common stock at $1.25 per share showing continued confidence and support of the business
FREEHOLD, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced the Company’s Chairman, Daniel Lu, has converted $3.0 million of debt owed to him under the Line of Credit into 2.4 million shares of the Company’s common stock at $1.25 per share. The conversion price represents a 45% premium to yesterday’s closing price.
$AVCO NEWS! Avalon GloboCare’s Chairman Converts Debt into Common Stock at 45% Premium to Market https://finance.yahoo.com/news/avalon-globocare-chairman-converts-debt-140000861.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
Holding green here!
AVCO
The “QTY Code” breakthrough technology, developed by Avalon and the laboratory of Dr. Shuguang Zhang, Ph.D., of MIT’s Media lab in Boston, MA, is a protein-design platform that can turn water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their use in many clinical applications, including drug development. This program has already successfully generated a series of decoy receptors, which function to soak up excess chemokines and cytokines produced in the body during a potentially fatal ‘cytokine storm.’ These cytokine storms can occur in patients with COVID-19 and in cancer patients being treated with CAR T-cell therapy.
AVCO
$AVCO Market Cap: $104 million
Outstanding Shares: 81 million
Float: 25.89 million
No debt
Approximate cash on hand as of Sept 2020: $20 million plus
Annual revenue from rental of extra commercial space: USD $1.2M. (In these early stages, Avalon for added revenue, also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth, development, as well as competitiveness in healthcare and CellTech industry markets.)
% of shares held by insiders: 71.30%
% of shares held by institutions: 3.46%
Joined Russell 3000 Index in June 2019
$AVCO big news here: Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy https://finance.yahoo.com/news/avalon-globocare-jointly-files-us-132000593.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
News: Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy
Avalon GloboCare Corp.
Thu, October 14, 2021, 9:20 AM
Co-developed novel technology platform combining S-layer proteins and emulsomes for diverse applications in bio-delivery of drugs and genes with the University of Natural Resources and Life Sciences (BOKU) Vienna
FREEHOLD, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced it has successfully co-developed a novel platform of S-layer coated emulsome technology (SLET) for next-generation drug delivery and cellular immunotherapy, together with Professor Uwe Sleytr and the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria.
Avalon and Professor Uwe Sleytr of BOKU have jointly filed USPTO (US63/060,235) and international PCT (US21/38327) patent applications pertaining to the novel SLET platform.
As a vesicular nano-carrier system, emulsomes are composed of an internal lipoidal core surrounded by phospholipid multilayers. This emulsome nano-carrier, when loaded with bio-active agents (such as poorly water-soluble pharmaceuticals and genetic materials, including DNA and RNA), may increase their solubility and bioavailability. This nano-formulation is also designed to be safe and nontoxic. The SLET platform exploits the S-layer fusion proteins as coating materials for the emulsome nano-carriers, in order to provide a “molecular GPS system” to guide the trafficking and delivery of the emulsomal payload to a targeted destination in the body. Avalon is actively exploring the practical uses of SLET, including targeted drug delivery, vaccine development, diagnostic devices, and cellular therapeutic applications.
“We are very excited to announce this novel SLET platform, which we believe will help accelerate the development of our mRNA-based Flash-CAR™ program. The targeted delivery of mRNA to immune effector cells by SLET could open the door to a whole new generation of cancer immunotherapy. In addition, we see a number of other therapeutic and diagnostic applications for this broad and potentially transformative technology platform. Moreover, we believe these latest patent filings will provide us robust international IP protection for this technology and its many potential applications,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare's developments, please follow our twitter at @avalongc_avco
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
avco@crescendo-ir.com
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com .
For the latest updates on Avalon GloboCare's developments, please follow our twitter at @avalongc_avco
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
avco@crescendo-ir.com
“Our partnership with BOKU researchers is yielding novel tools and discoveries that allow us to identify drug targets that have been traditionally out of reach due to the inability of existing technology to synthesize membrane proteins in a laboratory,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “This approach will expand our capabilities and repertoire in designing novel targets for immuno-oncology and cellular medicine,” added Dr. Jin.
The new technology is a direct result of a collaboration between the Company and researchers at BOKU, Vienna, the University of Vienna, the Science for Life Laboratory within the Division of Nanobiotechnology at the KTH Royal Institute of Technology in Stockholm, Sweden and the Department of Biochemistry at the King Abdulaziz University in Jeddah, Saudi Arabia. $AVCO
AVCO Technology will facilitate drug design for cancer and immune-related diseases
Very interesting to see what’s going to happen in the coming weeks
Would love to see a run above 1.30
Facts we all have but it’s definitely worth a buy
$AVCO Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for Cancer and Immune-Related Diseases
https://marketwirenews.com/news-releases/avalon-globocare-and-university-of-natural-resources-7006745211103303.html
I don't think you can go wrong at .87. LOL But I have been wrong before.
Heya Trip! I’m back in AVCO. Double bottom here and added 5k shares at 0.87. So I’m back on the AVCO train at least as a chart play
I sold out when the stock ran to 1.57 I got out at 1.45s and 1.43s. I did not like the news. Moved on.. Ive been focused on AMC for the past month and then some. Holding still from the $16s and 19s. But yea, was not thrilled about the AVCO news, and did not want to take a chance holding it, as it just became a more risk play for me. I timed it just right, as that day it ran up, it closed with the black candle of death. Anyways I am out of it now.
Hey Vipyr! You are much more up on things then I am now. What do you think of the takeover of Hebei Senlang Biotechnology? Do you think it makes sense?
I know we were down today but if we can find support right in this area of .98 that could be the beginning of higher lows. The 250 EMA has been a tough nut for AVCO to bust up through.
AVCO acquisition news.. Wish you were still here.
https://finance.yahoo.com/news/avalon-globocare-announces-execution-purchase-130000778.html
Wow, SIRC has gone from $3 down to .60 cents. You must have bought in before February.
For myself, I hold 5000 shares of AVCO now, but have begun shorting stocks like RAIL, and a few others. Time to start making money again, and this market is not normal. So decided myself to start playing the short side and that has been working out pretty awsome. The last 7 weeks have not been normal, and there is nothing normal about this market. The entire biotech sector has been heavily shorted some 90% or so.
I will not add anymore AVCO... It was a 3 year hold for me to begin with, but 1.04s were the last I added. I will keep those shares, and everything else I will be short selling. At least for the foreseeable future.
Good luck to you with SIRC, and hope it turns around... Im guessing you got in down in the .04 to .07 area. Nice one there$$$$
Best of luck back at ya... Catch ya around :)
Hello Vipyr...sorry for the radio silence and first time having a look at this board in a long time.
Yes...admittedly I did finally sell all my AVCO from my speculative accounts and put it into SIRC. It turned out to be a smart move.
I have not kept up with the fundamentals of AVCO but once I see it climb back above the daily 250 EMA will take another serious look at it..
Vipyr...wish you the best of luck!
New Article out on AVCO today. Avalon GloboCare seeking to tap the power of cells to fight cancer and coronavirus
https://www.proactiveinvestors.com//companies/news/901356/avalon-globocare-seeking-to-tap-the-power-of-cells-to-fight-cancer-and-coronavirus-901356.html?SNAPI
While it has been quiet so far in 2021, Avalon Globocare had a busy time in the final quarter of 2020
In October, the company announced the formation of a strategic collaboration for the global distribution of coronavirus (COVID-19) point-of-care antibody rapid test devices. It noted that the Assure/FaStep COVID-19 IgG/IgM Rapid Test Device is the first serology (antibody) POC test for COVID-19 using fingerstick blood samples approved by the US Food and Drug Administration (FDA).
The FDA has issued an emergency use authorization (EUA) for the test device as well as for the Assure/EcoStep COVID-19 IgG/IgM Rapid Test Device. Under the agreement, Adial has granted Avalon non-exclusive, sub-distribution rights worldwide for both tests. As a result of the FDA's EUA, fingerstick blood samples can now be utilized with the FaStep COVID-19 IgG/IgM Rapid Test Device for the test in POC settings, including doctors' offices, hospitals, urgent care centers, emergency rooms, or other locations where there is a licensed healthcare professional.
In the December 2020 issue of Nature’s Biopharma Dealmakers, Avalon’s president and CEO, Dr David Jin, highlighted Avalon’s ongoing scientific and clinical developments including a first-in-human trial of a mucosal, intranasal vaccine against SARS-CoV-2 that is planned for early 2021.
In September, Avalon had announced the launch of its new allogeneic mesenchymal stromal cell (MSC) therapeutic platform as a potential therapy for COVID-19 which is caused by the SARS-CoV-2 virus. The company said it believes that its MSC platform could offer a unique and efficacious approach to treat the potentially fatal acute respiratory distress syndrome, multi-system inflammatory syndrome and cytokine storm-related to severe cases of COVID-19.
In addition to being a potential therapy for COVID-19, the company said the platform would also be developed to treat bone marrow transplant-related complications of acute graft versus host disease (aGVHD).
In the December Nature Biopharma Dealmakers issue, Dr Jin also described the company’s innovative, allogeneic mesenchymal stromal cell (MSC) therapy candidate, CB-MSC-1, which possess unique anti-inflammatory and immunomodulatory activities, as well as AVA-001, Avalon’s third-generation CAR T cell therapy that has shown robust activity in patients with relapsed, refractory B cell acute lymphoblastic leukemia in a Phase 1 trial.
At the start of October, Avalon said it had expanded the Phase 1 clinical trial of its relapsed/refractory B-cell lymphoblastic leukemia treatment, AVA-001, to include enrollment of patients with relapsed/refractory non-Hodgkin lymphoma. AVA-001 is a chimeric antigen receptor (CAR) T-cell (a type of white blood cell) therapy and allogeneic mesenchymal stromal cell (MSC, or connective tissue) therapy, which is designed to improve the body’s capacity to kill cancer cells.
In June, Avalon had successfully completed a first-in-human trial of the drug, and found that nine out of 10 patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) achieved complete remission within one month.
And at the end of December, Avalon also provided an update on its partnership with the Institute for Synthetic Bioarchitectures at the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria.
The collaboration brings together BOKU’s S-layer nanotechnology with Avalon’s expertise in biomanufacturing, cell therapy engineering, and clinical development. Avalon plans to leverage the pioneering work of Professor Uwe B. Sleytr, a world-renowned scientist and pioneer in nanobiotechnology, who is among the foremost experts on basic and applied surface layer (S-layer) technology, and Professor Emeritus in the Department of Nanobiotechnology at BOKU. Professor Sleytr is also a member of Avalon’s Scientific and Clinical Advisory Board.
Avalon and BOKU are establishing a state-of-the-art research facility, the Christian Doppler Laboratory, located on the BOKU campus in Vienna, Austria, under the scientific leadership of Professor Eva-Kathrin Ehmoser, the Head of BOKU’s Institute for Synthetic Bioarchitectures and Professor Sleytr, a member of the Austrian Academy of Sciences. In connection with the new facility, Avalon and BOKU have signed a Memorandum of Understanding (MOU) to jointly apply for a matching research grant from the prestigious Christian Doppler Laboratory Foundation.
Heya Trip, do you know why AVCO has a new investor relations firm?
Crescendo Communications, LLC
T: (212) 671-1020
avco@crescendo-ir.com
Any idea whats going on? I know its got a very nice dragonfly doji reversal signal on the charts.
Dragonfly doji at bottom of the major downtrend signals reversal here.
Ya know, I am beginning to wonder if this company is still alive. 2 months without a PR. Kroger closing their stores from what I hear.. AVCO had a partnership with Adial Pharma, whom had the Kroger Pharmacy gig. I dont know what is going on with this one anymore.
Really do not know what is going on with this stock.. As there is a great deal of erratic trading going on here. And no news for almost 2 months? Just when you think this stock can hold the line, it looks like 1.33s coming again.
AVCO absolutely getting blistered this week. Wow.
Looks like AVCO going to gap up abit
What is going on? Almost 1 million volume 3 hours into the markets... AVCO way up.... Yippie
Agree. I am ready for the next leg up. It would be ideal for news to break tomorrow :) $$$$ But again, I am long, an I am glad that I added blocks in the 1.20s here the last time down. I am no longer in the red on this stock.. Dont matter, Im holding no matter what
I think AVCO set up very well today. If I see it holding above the 250 EMA in the morning I will be adding to my position. Ideally would like to see more volume start to come in soon...
I did not even realize AVCO hit 1.60 yesterday.. Wow.
Everything I have is red today... was to be expected after the last 2 biblical days LOL.. I had stops set just below support on all of my stocks except AVCO, and none of them triggered so its not too bad of a day. And AVCO is holding the 250 day after coming down near to test it at 1.47, close to the 1.45 EMA
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
667
|
Created
|
03/07/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |